Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Am J Nephrol. 2013;37(5):399-404. doi: 10.1159/000349930. Epub 2013 Apr 3.
Metabolic syndrome (MetS) is common among kidney transplant patients. We studied the relationship between MetS, vitamin D deficiency/insufficiency and hypoadiponectinemia early posttransplantation and their impact on clinical outcomes.
Seventy-four previously nondiabetic kidney transplant patients were enrolled in a prospective cohort study between February and November 2008. Participants underwent a 2-hour oral glucose tolerance test and had their plasma levels of 25-hydroxyvitamin D (25[OH]D), adiponectin, insulin, intact parathyroid hormone and lipids measured at 11 weeks posttransplantation. Clinical events including cardiovascular events, new-onset diabetes after transplantation, acute rejection, graft loss and death were recorded during the follow-up to December 2012.
Thirty-four study patients (45.9%) had MetS. Patients with MetS had lower plasma concentrations of 25[OH]D (20.5 ± 7.2 vs. 24.8 ± 11.1 ng/ml, p = 0.049) and adiponectin (8.2 ± 4.5 vs. 14.6 ± 8.0 μg/ml, p < 0.0001) early on, and higher composite clinical event rate (61.8 vs. 27.5%, p = 0.003) during the follow-up. Multivariate analysis showed that the presence of MetS early after transplantation was independently associated with 25[OH]D deficiency/insufficiency (OR: 14.0, 95% CI: 1.8, 107.5; p = 0.011), depressed plasma adiponectin levels (β -6.39, r(2) 0.195, p < 0.0001) and increased risk for clinical events (OR: 5.6, 95% CI: 1.9, 16.5; p = 0.002).
Kidney transplant patients with MetS early after transplantation had lower levels of 25[OH]D and adiponectin, and unfavorable clinical outcomes.
代谢综合征(MetS)在肾移植患者中较为常见。本研究旨在探讨移植后早期 MetS、维生素 D 缺乏/不足和脂联素减少的关系及其对临床结局的影响。
2008 年 2 月至 11 月,我们纳入了 74 例先前无糖尿病的肾移植患者进行前瞻性队列研究。所有患者在移植后 11 周时进行 2 小时口服葡萄糖耐量试验,并检测其血浆 25-羟维生素 D(25[OH]D)、脂联素、胰岛素、全段甲状旁腺激素和血脂水平。在 2012 年 12 月前随访期间,记录心血管事件、移植后新发糖尿病、急性排斥反应、移植物丢失和死亡等临床事件。
34 例(45.9%)患者存在 MetS。与无 MetS 者相比,MetS 患者的血浆 25[OH]D 水平更低[20.5 ± 7.2 比 24.8 ± 11.1ng/ml,p = 0.049],脂联素水平更低[8.2 ± 4.5 比 14.6 ± 8.0μg/ml,p < 0.0001],且复合临床事件发生率更高[61.8%比 27.5%,p = 0.003]。多因素分析显示,移植后早期 MetS 与 25[OH]D 缺乏/不足(OR:14.0,95%CI:1.8,107.5;p = 0.011)、脂联素水平降低(β-6.39,r(2) 0.195,p < 0.0001)和临床事件风险增加(OR:5.6,95%CI:1.9,16.5;p = 0.002)独立相关。
移植后早期存在 MetS 的肾移植患者的 25[OH]D 和脂联素水平更低,临床结局更差。